AR071112A1 - Derivados de benzopirano y benzoxepina inhibidores de quinasaspi3k, utiles como agentes anticancer,y composiciones farmaceuticas que los contienen. - Google Patents
Derivados de benzopirano y benzoxepina inhibidores de quinasaspi3k, utiles como agentes anticancer,y composiciones farmaceuticas que los contienen.Info
- Publication number
- AR071112A1 AR071112A1 ARP090101126A ARP090101126A AR071112A1 AR 071112 A1 AR071112 A1 AR 071112A1 AR P090101126 A ARP090101126 A AR P090101126A AR P090101126 A ARP090101126 A AR P090101126A AR 071112 A1 AR071112 A1 AR 071112A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkylene
- nr10r11
- co2h
- ch2oh
- heterocyclyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Abstract
Son utiles para inhibir quinasas lipídicas que incluyen p110 alfa y otras isoformas de PI3K, y para tratar trastornos tales como cáncer mediado por quinasas lipídicas. Reivindicacion 1: Un compuesto seleccionado de formula 1 y sus estereoisomeros, isomeros geométricos, tautomeros, o sales aceptables para uso farmacéutico, donde: Z1 es CR1 o N; Z2 es CR2 o N; Z3 es CR3 o N; Z4 es CR4 o N; donde (i) X1 es N y X2 es S, (ii) X1 es S y X2 es N, (iii) X1 es CR7 y X2 es S, o (iv) X1 es S y X2 es CR7; R1, R2, R3, R4, y R7 se seleccionan independientemente entre H, F, CI, Br, I, -CN, -CF3, -CH2OR10, -CH2R10, -alquileno C1-12NR10R11, -alquileno C1-12NR12C(=O)R10, -alquileno C1-12C(=O)OR10, -alquileno C1-12OR10, -CO2R10, -C(=O)N(R10)OR11, -NO2, -NR10R11, -OR10, -S(O)2R10, -C(=O)NR10R11, -C(=O)NR10(alquileno C1-12)NR10R11, -C(=O)NR10(alquileno C1-12)NR10C(=O)OR11, -C(=O)NR10(alquileno C1-12)NR10C(=O)R11, -C(=O)NR10(alquileno C1-12)R10, -C(=NR10)NR10R11, -NR12C(=O)R10, -NR12C(=O)OR11, -NR12C(=O)NR10R11, -NR12C(=O)(alquileno C1-12)NR10R11, -NR12(alquileno C1-12)NR10R11, -NR12(alquileno C1-12)OR10, -NR12(alquileno C1-12)C(=O)NR10R11, -C=CR10, -CH=CHR10, heterociclilo C2-20, heteroarilo C1-20, y fenilo, donde heterociclilo, heteroarilo, y fenilo están opcionalmente sustituidos con uno o más grupos seleccionados entre F, CI, Br, I, -CH2OH, -(CH2)2OH, -CH2CO2H, -CN, -CH2NH2, -(CH2)2N(CH3)2, -CH3, -C(=O)CH3, -C(=O)NHCH3, -CO2H, -CH2CO2CH3, -NH2, -OCH3, -S(O)2CH3, 4-metilpiperazin-1-ilo, y 4-morfolinilo, y donde alquileno está opcionalmente sustituido con uno o más F; A se selecciona entre -C(O)NR5R6, heterociclilo C2-20 y heteroarilo C1-20 donde heterociclilo C2-20 y heteroarilo C1-20 están opcionalmente sustituidos con uno o más grupos seleccionados independientemente entre F, CI, Br, I, -CH2OH, -CH2CO2H, -CH(CH3)CH2OCH3, -CN, alquilo C1-12, -alquileno C1-12NR10R11, -alquileno C1-12OR10, -CH3, -C(=O)CH3, -C(=O)NHCH3, -C(=O)N(CH3)2, -CO2H, -CO2CH3, -CH2CO2CH3, -NH2, -NHC(=O)CH3, -OCH3, -S(O)2CH3, 1-metilpiperid-4-ilo, 4-metilpiperazin-1-ilo, 4-morfolinilo, isopropilo, isobutilo, ciclopropilo, ciclopropilmetilo, ciclobutilo, triazolilmetilo, bencilo, y fenilo, donde alquilo, alquileno, bencilo y fenilo están opcionalmente sustituidos con uno o más grupos seleccionados independientemente entre F, CI, Br, I, -CF3, -CH2OH, -CH2CO2H, -CN, -CH2NH2, -CH3, -C(=O)CH3, -C(=O)NHCH3, -CO2H, -CH2CO2CH3, -NH2, -OH, -OCH3, -S(O)2CH3, 1-metilpiperid-4-ilo, (4-metilpiperazin-1-il)carboxamida, -CH2(1H-1,2,4-triazol-5-il), 4-metilpiperazin-1-ilo, y 4-morfolinilo; R5 se selecciona entre H, alquilo C1-12, opcionalmente sustituido con uno o más grupos seleccionados independientemente entre F, CI, Br, I, -CN, -CO2H, -CONH2, -CONHCH3, -NH2, -NO2, -N(CH3)2, -NHCOCH3, -NHS(O)2CH3, -OH, -OCH3, -OCH2CH3, -S(O)2NH2, y -S(O)2CH3; R6 se selecciona entre alquilo C1-12, carbociclilo C3-12, heterociclilo C2-20, heteroarilo C1-20, y arilo C6-20, cada uno opcionalmente sustituido con uno o más grupos seleccionados independientemente entre F, CI, Br, I, -CH2OH, - CH2C6H5, -CN, -CF3, -CO2H, -C(=O)NR10R11, -NH2, -NO2, -N(CH3)2, -NHCOCH3, -NHS(O)2CH3, -OH, -OCH3, -OCH2CH3, -S(O)2NH2, -S(O)2CH3, -C(=O)NR10(alquileno C1-12)NR10R11, morfolin-4-ilo, piperidin-1-ilo, piperazinilo, piperazin-4-il-2-ona, piperazin-4-il-3-ona, pirrolidin-1-ilo, tiomorfolin-4-ilo, S-dioxotiomorfolin-4-ilo, -C:::CR13, -CH=CHR13, y -C(=O)NR10R11 o R5 y R6 junto con el átomo de nitrogeno al cual están unidos forman morfolin-4-ilo, piperidin-1-ilo, piperazinilo, piperazin-4-il-2-ona, piperazin-4-iI-3-ona, pirrolidin-1-ilo, tiomorfolin-4-ilo o S-dioxotiomorfolin-4-ilo, cada uno opcionalmente sustituido con uno o más grupos seleccionados entre F, CI, Br, I, -CH2OH, -CH2C6H5, -CN, -CF3, -CO2H, -CONH2, -CONHCH3, -NO2, - N(CH3)2, -NHCOCH3, -NHS(O)2CH3, -OH, -OCH3, -OCH2CH3, -S(O)2NH2, y -S(O)2CH3; R7 se selecciona entre H y F; R10, R11 y R12 se seleccionan independientemente entre H, alquilo C1-12, alquilen C1-12-heterociclilo C2-20, alquilen C1-12-arilo C6-20, alquenilo C2-8, alquinilo C2-8, carbociclilo C3-12, heterociclilo C2-20, arilo C6-20, y heteroarilo C1-20, donde alquilo C1-12, alquenilo C2-8, alquinilo C2-8, carbociclilo C3-12, heterociclilo C2-20, arilo C6-20, y heteroarilo C1-20 están opcionalmente sustituidos con uno o más grupos seleccionados independientemente entre F, CI, Br, I, -CH2OH, -CH2C6H5, -CN, -CF3, -CO2H, -CONH2, -CONHCH3, -NO2, -N(CH3)2, -NHCOCH3, -NHS(O)2CH3, -OH, -OCH3, -OCH2CH3, 2-oxopirrolidin-1-ilo, -S(O)2NH2, y -S(O)2CH3; o R10 y R11 junto con el átomo de nitrogeno al cual están unidos forman un anillo de heterociclilo C2-20 o heteroarilo C1-20 cada uno opcionalmente sustituido con uno o más grupos seleccionados independientemente entre F, CI, Br, I, -CH3, -CH2OH, -CH2C6H5, -CN, -CF3, -CO2H, -CONH2, -CONHCH3, -NO2, -N(CH3)2, -NHCOCH3, -NHS(O)2CH3, -OH, oxo, -OCH3, -OCH2CH3, -S(O)2NH2, y -S(O)2CH3; y R13 se selecciona entre H, F, CI, Br, I, -CH3, -CH2CH3, -CN, -CF3, -CH2N(CH3)2, -CH2OH, -CO2H, -CONH2, -CON(CH3)2, -NO2, y -S(O)2CH3. Reivindicacion 32: Un compuesto seleccionado de la formula (2) y sus estereoisomeros, isomeros geométricos, tautomeros, o sales aceptables para uso farmacéutico, donde: R1, R2, R3, y R4 se seleccionan independientemente entre H, F, CI, Br, I, -CN, -CF3, -CH2OR10, -CH2R10, -CH2NR10R11, -(alquileno C1-12)C(=O)OR10, -CO2R10, -C(=O)N(R10)OR11, -NO2, -NR10R11, -OR10, -S(O)2R10, -C(=O)NR10R11, -C(=O)NR10(alquileno C1-12)NR10R11, -C(=O)NR10(alquileno C1-12)NR10C(=O)OR11, -C(=O)NR10(alquileno C1-12)NR10C(=O)R11, -C(=O)NR10(alquileno C1-12)R10, -NR12C(=O)R10, -NR12C(=O)OR11, -NR12C(=O)NR10R11, -NR12(alquileno C1-12)NR10R11, -NR12(alquileno C1-12)OR10, -NR12(alquileno C1-12)C(=O)NR10R11, -C:::CR10, -CH=CHR10, heterociclilo C2-20, heteroarilo C1-20, y fenilo, donde heterociclilo, heteroarilo, y fenilo están opcionalmente sustituidos con uno o más grupos seleccionados entre -CH2OH, -CH2CO2H, -CN, -CH2NH2, -C(=O)CH3, -CO2H, -CH2CO2CH3; -NH2, -S(O)2CH3, 4-metilpiperazin-1-ilo, y 4-morfolinilo; R5 se selecciona entre alquilo C1-12, opcionalmente sustituido con uno o más grupos seleccionados independientemente entre F, CI, Br, I, -CN, -CO2H, -CONH2, -CONHCH3, -NH2, -NO2, -N(CH3)2, -NHCOCH3, -NHS(O)2CH3, -OH, -OCH3, -OCH2CH3, -S(O)2NH2, y -S(O)2CH3; R6 se selecciona entre carbociclilo C3-12, heterociclilo C2-20, heteroarilo C1-20, y arilo C6-20, cada uno opcionalmente sustituido con uno o más grupos seleccionados independientemente entre F, CI, Br, I, -CH2OH, -CH2C6H5, -CN, -CF3, -CO2H, -CONHCH3, -NH2, -NO2, -N(CH3)2, -NHCOCH3, -NHS(O)2CH3, -OH, -OCH3, -OCH2CH3, -S(O)2NH2, -S(O)2CH3, morfolin-4-ilo, piperidin-1-ilo, piperazinilo, piperazin-4-il-2-ona, piperazin-4-il-3-ona, pirrolidin-1-ilo, tiomorfolin-4-ilo, S-dioxotiomorfolin-4-ilo, -C:::CR13, -CH=CHR13, y -C(=O)NR10R11 o R5 y R6 junto con el átomo de nitrogeno al cual están unidos forman morfolin-4-ilo, piperidin-1-ilo, piperazinilo, piperazin-4-il-2-ona, piperazin-4-iI-3-ona, pirrolidin-1-ilo, tiomorfolin-4-ilo, S-dioxotiomorfolin-4-ilo, cada uno opcionalmente sustituido con uno o más grupos seleccionados entre F, CI, Br, I, -CH2OH, -CH2C6H5, -CN, -CF3, -CO2H, -CONH2, -CONHCH3, -NO2, - N(CH3)2, -NHCOCH3, -NHS(O)2CH3, -OH, -OCH3, -OCH2CH3, -S(O)2NH2, y -S(O)2CH3;cada uno R7 se selecciona independientemente entre H, F, Cl, Br, I, -CH2OH, -CH3, -CN, -CF3, -CO2H, -CONH2, -CONHCH3, -NO2, -N(CH3)2, -NHCOCH3, -NHS(O)2CH3, -OH, -OCH3, -OCH2CH3, -S(O)2NH2, y -S(O)2CH3; o ambos R7 juntos son =O; R8 se selecciona entre H y F; R10, R11 y R12 se seleccionan independientemente entre H, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, carbociclilo C3-12, heterociclilo C2-20, arilo C6-20, y heteroarilo C1-20, donde alquilo C1-12, alquenilo C2-8, alquinilo C2-8, carbociclilo C3-12, heterociclilo C2-20, arilo C6-20, y heteroarilo C1-20 están opcionalmente sustituidos con uno o más grupos seleccionados independientemente entre F, CI, Br, I, -CH2OH, -CH2C6H5, -CN, -CF3, -CO2H, -CONH2, -CONHCH3, -NO2, -N(CH3)2, -NHCOCH3, -NHS(O)2CH3, -OH, -OCH3, -OCH2CH3, -S(O)2NH2, y -S(O)2CH3; o R10 y R11 junto con el átomo de nitrogeno al cual están unidos forman un anillo de heterociclilo C2-20 opcionalmente sustituido con uno o más grupos seleccionados independientemente entre F, CI, Br, I, -CH3, -CH2OH, -CH2C6H5, -CN, -CF3, -CO2H, -CONH2, -CONHCH3, -NO2, -N(CH3)2, -NHCOCH3, -NHS(O)2CH3, -OH, oxo, -OCH3, -OCH2CH3, -S(O)2NH2, y -S(O)2CH3; R13 se selecciona entre H, F, CI, Br, I, -CH3, -CH2CH3, -CN, -CF3, -CH2N(CH3)2, -CH2OH, -CO2H, -CONH2, -CON(CH3)2, -NO2, y -S(O)2CH3; n es 1 o 2; y Y es O, S, N-NR10R11; con las siguientes condiciones: cuando n es 1, Y es O, y R1, R2, R3, R7, R8 son cada uno H, entonces R4 no es H o CH3 y cuando n es 1, entonces ambos R7 en forma conjunta no son =O.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4082708P | 2008-03-31 | 2008-03-31 | |
US10222008P | 2008-10-02 | 2008-10-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR071112A1 true AR071112A1 (es) | 2010-05-26 |
Family
ID=40790991
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090101126A AR071112A1 (es) | 2008-03-31 | 2009-03-30 | Derivados de benzopirano y benzoxepina inhibidores de quinasaspi3k, utiles como agentes anticancer,y composiciones farmaceuticas que los contienen. |
Country Status (22)
Country | Link |
---|---|
US (4) | US7928248B2 (es) |
EP (1) | EP2276767B1 (es) |
JP (1) | JP5511786B2 (es) |
KR (1) | KR101626996B1 (es) |
CN (1) | CN102333779B (es) |
AR (1) | AR071112A1 (es) |
AU (1) | AU2009231885B2 (es) |
BR (1) | BRPI0910346A2 (es) |
CA (1) | CA2719032C (es) |
CL (1) | CL2009000780A1 (es) |
DK (1) | DK2276767T3 (es) |
ES (1) | ES2480994T3 (es) |
HK (1) | HK1147741A1 (es) |
IL (1) | IL208359A (es) |
MX (1) | MX2010010659A (es) |
PE (1) | PE20091720A1 (es) |
PL (1) | PL2276767T3 (es) |
RU (1) | RU2506267C2 (es) |
SI (1) | SI2276767T1 (es) |
TW (1) | TWI443102B (es) |
WO (1) | WO2009123971A1 (es) |
ZA (1) | ZA201007218B (es) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5581219B2 (ja) | 2008-01-25 | 2014-08-27 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | チオフェンおよびホスファチジルイノシトール3−キナーゼ(pi3k)阻害薬としてのその使用 |
CN102333779B (zh) | 2008-03-31 | 2015-12-09 | 吉宁特有限公司 | 苯并吡喃和苯并氧杂*pi3k抑制剂化合物和使用方法 |
WO2010090716A1 (en) | 2009-01-30 | 2010-08-12 | Millennium Pharmaceuticals, Inc. | Heteroaryls and their use as pi3k inhibitors |
US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
US8796314B2 (en) | 2009-01-30 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
US20100233733A1 (en) * | 2009-02-10 | 2010-09-16 | Nodality, Inc., A Delaware Corporation | Multiple mechanisms for modulation of the pi3 kinase pathway |
EA201200087A1 (ru) * | 2009-07-02 | 2012-07-30 | Новартис Аг | 2-карбоксамиды циклоаминомочевин, которые являются ингибиторами pi3k |
SG10201405049RA (en) | 2009-09-28 | 2014-10-30 | Hoffmann La Roche | Benzoxazepin pi3k inhibitor compounds and methods of use |
BR112012006802A2 (pt) * | 2009-09-28 | 2020-08-18 | F.Hoffmann-La Roche Ag | composto, composição farmacêutica, método para tratar câncer, usos de um composto, kit e invenção |
WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
ES2759949T3 (es) * | 2009-10-29 | 2020-05-12 | Bristol Myers Squibb Co | Compuestos heterocíclicos tricíclicos |
EA036876B1 (ru) | 2009-11-05 | 2020-12-30 | Ризен Фармасьютикалз С.А. | Ингибиторы pi3k киназы |
AR078979A1 (es) * | 2009-11-13 | 2011-12-14 | Merck Serono Sa | Derivados de triciclo pirazol amina |
US9072783B2 (en) | 2009-11-18 | 2015-07-07 | Aridis Pharmaceuticals | Highly dispersible powders, compositions and methods for preparation |
US8796271B2 (en) | 2010-08-11 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
EP2603216A4 (en) | 2010-08-11 | 2013-12-18 | Millennium Pharm Inc | HETEROARYLE AND USES THEREOF |
US9062038B2 (en) | 2010-08-11 | 2015-06-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
EA201390539A1 (ru) | 2010-10-13 | 2013-09-30 | Милленниум Фармасьютикалз, Инк. | Гетероарилы и их применение |
KR20140032383A (ko) | 2011-03-21 | 2014-03-14 | 에프. 호프만-라 로슈 아게 | Pi3k p110 델타에 대하여 선택적인 벤즈옥사제핀 화합물 및 이의 사용 방법 |
SI2705029T1 (sl) | 2011-05-04 | 2019-03-29 | Rhizen Pharmaceuticals S.A. | Nove spojine kot modulatori protein-kinaz |
CA2837084C (en) * | 2011-05-27 | 2019-09-17 | Lexicon Pharmaceuticals, Inc. | 4h-thieno[3,2-c]chromene-based inhibitors of notum pectinacetylesterase and methods of their use |
KR20140131359A (ko) | 2012-02-17 | 2014-11-12 | 에프. 호프만-라 로슈 아게 | 트라이사이클릭 화합물 및 이의 사용 방법 |
US8940742B2 (en) * | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US20170002313A1 (en) | 2012-05-23 | 2017-01-05 | Genentech Inc. | Compositions and methods of obtaining and using endoderm and hepatocyte cells |
SG10201704048UA (en) | 2012-07-04 | 2017-06-29 | Rhizen Pharmaceuticals Sa | Selective pi3k delta inhibitors |
US20150258127A1 (en) | 2012-10-31 | 2015-09-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
MX2015011438A (es) | 2013-03-13 | 2016-02-03 | Hoffmann La Roche | Procedimiento para preparar compuestos benzoxazepina. |
CA2905123A1 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Methods of treating cancer and preventing cancer drug resistance |
US11491154B2 (en) | 2013-04-08 | 2022-11-08 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
MY175778A (en) | 2013-10-04 | 2020-07-08 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof |
SG11201607705XA (en) | 2014-03-19 | 2016-10-28 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
LT3230289T (lt) | 2014-12-11 | 2019-10-10 | Natco Pharma Limited | 7-(morfolinil)-2-(n-piperazinil)metiltieno[2, 3-c]piridino dariniai kaip priešvėžiniai vaistai |
CA2980266A1 (en) | 2015-03-30 | 2016-10-06 | Jubilant Biosys Limited | Tricyclic fused derivatives of 1-(cyclo)alkyl pyridin-2-one useful for the treatment of cancer |
KR20180058741A (ko) | 2015-09-14 | 2018-06-01 | 인피니티 파마슈티칼스, 인코포레이티드 | 이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법 |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
KR102482825B1 (ko) | 2016-09-02 | 2022-12-29 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 트리시클릭 헤테로시클릭 화합물 |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
CA3070073A1 (en) | 2017-07-18 | 2019-01-24 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
US11028058B2 (en) | 2017-07-18 | 2021-06-08 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
US11059784B2 (en) | 2017-08-09 | 2021-07-13 | Bristol-Myers Squibb Company | Oxime ether compounds |
US11046646B2 (en) | 2017-08-09 | 2021-06-29 | Bristol-Myers Squibb Company | Alkylphenyl compounds |
CN107805255B (zh) * | 2017-09-22 | 2020-06-16 | 中国药科大学 | 呋喃[3,2-b]吡啶-2(1H)-酮类化合物、制备方法和医药用途 |
US20210017174A1 (en) | 2018-03-07 | 2021-01-21 | Bayer Aktiengesellschaft | Identification and use of erk5 inhibitor |
CN110467629B (zh) * | 2018-05-09 | 2022-04-08 | 上海迪诺医药科技有限公司 | 苯醌衍生物、其药物组合物及应用 |
CN113939291A (zh) | 2019-01-18 | 2022-01-14 | 诺维逊生物股份有限公司 | 1,8-萘啶酮化合物及其用途 |
BR112021013936A2 (pt) | 2019-01-18 | 2021-09-21 | Nuvation Bio Inc. | Compostos heterocíclicos como antagonistas de adenosina |
CN114156414A (zh) * | 2021-11-30 | 2022-03-08 | 合肥工业大学 | 一种高效稳定CsPbI3无机钙钛矿电池的制备方法 |
CN115403591A (zh) * | 2022-10-08 | 2022-11-29 | 河南师范大学 | 一种合成萘并噻吩并奥塞平并异喹啉酮类化合物的方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8504702D0 (en) | 1985-02-23 | 1985-03-27 | Zyma Sa | Tricyclic compounds |
FR2677356B1 (fr) | 1991-06-05 | 1995-03-17 | Sanofi Sa | Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant. |
ES2102195T3 (es) | 1992-12-28 | 1997-07-16 | Eisai Co Ltd | Derivados heterociclicos de acido carbonico que se fijan en receptores de retinoides. |
WO1997019087A1 (en) | 1995-11-17 | 1997-05-29 | E.I. Du Pont De Nemours And Company | Tricyclic herbicidal heterocycles |
DE19831878C2 (de) * | 1998-07-17 | 2001-05-17 | Aventis Pharma Gmbh | Polycyclische Thiazolidin-2-yliden Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE19908533A1 (de) | 1999-02-26 | 2000-08-31 | Aventis Pharma Gmbh | Polycyclische Thiazol-Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen |
DE19908535A1 (de) | 1999-02-26 | 2000-08-31 | Aventis Pharma Gmbh | Verwendung von polycyclischen Thiazol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas |
DE19908538A1 (de) | 1999-02-26 | 2000-08-31 | Aventis Pharma Gmbh | Polycyclische 2-Amino-Thiazol Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen |
DE19908537A1 (de) | 1999-02-26 | 2000-08-31 | Aventis Pharma Gmbh | Verwendung von polycyclischen 2-Amino-Thiazol Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas |
US7273880B2 (en) | 1999-06-30 | 2007-09-25 | H. Lunbeck A/S | Selective NPY (Y5) antagonists |
WO2001064675A1 (en) | 2000-03-03 | 2001-09-07 | Novartis Ag | Condensed thiazolamines and their use as neuropeptide y5 antagonists |
JPWO2002098863A1 (ja) * | 2001-06-05 | 2004-09-16 | 藤沢薬品工業株式会社 | 縮合イミダゾール誘導体 |
US20040082602A1 (en) | 2002-07-19 | 2004-04-29 | Hagen Timothy J. | Substituted thiophene carboxamide compounds for the treatment of inflammation |
WO2004069245A1 (en) | 2003-02-07 | 2004-08-19 | Warner-Lambert Company Llc | Oxazolidinone derivates n-substituted by a tricyclic ring, for use as antibacterial agents |
RU2403258C2 (ru) | 2004-10-07 | 2010-11-10 | Бёрингер Ингельхайм Интернациональ Гмбх | Тиазолилдигидроиндазолы |
CN101039667A (zh) * | 2004-10-15 | 2007-09-19 | 辉瑞大药厂 | 双相性精神障碍和相关症状的治疗 |
RU2281947C1 (ru) * | 2005-07-05 | 2006-08-20 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Аннелированные карбамоилазагетероциклы, фокусированная библиотека, фармацевтическая композиция и способ получения |
CA2659956C (en) | 2006-08-04 | 2016-01-05 | Lewis C. Cantley | Inhibitors of pyruvate kinase and methods of treating disease |
US8779154B2 (en) * | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
CN102333779B (zh) | 2008-03-31 | 2015-12-09 | 吉宁特有限公司 | 苯并吡喃和苯并氧杂*pi3k抑制剂化合物和使用方法 |
-
2009
- 2009-03-30 CN CN200980120112.8A patent/CN102333779B/zh active Active
- 2009-03-30 TW TW098110447A patent/TWI443102B/zh not_active IP Right Cessation
- 2009-03-30 MX MX2010010659A patent/MX2010010659A/es active IP Right Grant
- 2009-03-30 CA CA2719032A patent/CA2719032C/en not_active Expired - Fee Related
- 2009-03-30 JP JP2011503076A patent/JP5511786B2/ja active Active
- 2009-03-30 US US12/414,403 patent/US7928248B2/en active Active
- 2009-03-30 SI SI200930981T patent/SI2276767T1/sl unknown
- 2009-03-30 RU RU2010143319/04A patent/RU2506267C2/ru not_active IP Right Cessation
- 2009-03-30 AR ARP090101126A patent/AR071112A1/es not_active Application Discontinuation
- 2009-03-30 PE PE2009000466A patent/PE20091720A1/es not_active Application Discontinuation
- 2009-03-30 AU AU2009231885A patent/AU2009231885B2/en not_active Ceased
- 2009-03-30 BR BRPI0910346A patent/BRPI0910346A2/pt not_active IP Right Cessation
- 2009-03-30 DK DK09726963.3T patent/DK2276767T3/da active
- 2009-03-30 EP EP09726963.3A patent/EP2276767B1/en active Active
- 2009-03-30 WO PCT/US2009/038795 patent/WO2009123971A1/en active Application Filing
- 2009-03-30 PL PL09726963T patent/PL2276767T3/pl unknown
- 2009-03-30 ES ES09726963.3T patent/ES2480994T3/es active Active
- 2009-03-30 CL CL2009000780A patent/CL2009000780A1/es unknown
- 2009-03-30 KR KR1020107024488A patent/KR101626996B1/ko not_active IP Right Cessation
-
2010
- 2010-10-03 IL IL208359A patent/IL208359A/en not_active IP Right Cessation
- 2010-10-08 ZA ZA2010/07218A patent/ZA201007218B/en unknown
-
2011
- 2011-01-31 US US13/018,068 patent/US8399690B2/en active Active
- 2011-02-22 HK HK11101741.7A patent/HK1147741A1/xx unknown
-
2013
- 2013-01-10 US US13/738,846 patent/US8846762B2/en active Active
-
2014
- 2014-07-29 US US14/446,154 patent/US9309265B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR071112A1 (es) | Derivados de benzopirano y benzoxepina inhibidores de quinasaspi3k, utiles como agentes anticancer,y composiciones farmaceuticas que los contienen. | |
ES2530545T3 (es) | Compuestos tricíclicos inhibidores de la PI3K y métodos de uso | |
AR078187A1 (es) | Derivados heterociclicos de benzoxazepina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer. | |
HRP20171453T1 (hr) | Derivati imidazotiadiazola i imidazopirazina kao inhibitori proteazom aktiviranog receptora 4 (par4) za liječenje agregacije trombocita | |
ES2855732T3 (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad de NLRP | |
PE20161443A1 (es) | Compuestos | |
CL2017001422A1 (es) | Pirazolo [1,5-a] pirazinas 4,6-sustituidas como inhibidores de janus cinasas | |
PE20190509A1 (es) | 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas | |
CO5700824A2 (es) | Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen | |
PE20200388A1 (es) | Amidas heterociclicas de 5 miembros y biciclicas como inhibidores de rock | |
CL2013002690A1 (es) | Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
PH12016501440A1 (en) | Novel heterocyclic compounds | |
ECSP12011752A (es) | Compuestos de benzoxepina inhibidores de la pi3k y métodos de uso | |
AR084507A1 (es) | Derivados de indazoliltriazol | |
AR077975A1 (es) | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina | |
PE20160869A1 (es) | Derivados novedosos de amino pirimidina | |
PE20150767A1 (es) | Inhibidores de gdf-8 | |
AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
AR064476A1 (es) | Derivados de 1h-pirrolo[2, 3-b]piridina sustituidos, composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por a-raf, b-raf y/o por c-raf-1. | |
AR045536A1 (es) | Inhibidores de la fosfodiesterasa tipo -iv | |
EA201490807A1 (ru) | Новые замещенные имидазопиримидины как модуляторы рецептора gpbar1 | |
BR112019021853A2 (pt) | Compostos de inibidor de vmat2 e composições dos mesmos | |
ECSP11011201A (es) | Combinaciones que comprenden metotrexato e inhibidores de dhodh | |
PE20170682A1 (es) | Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados utiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncologicas y autoinmunitarias | |
PE20190339A1 (es) | 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |